GET THE APP

Direct Determination of Four ACE-Inhibitors Lisinopril, Enalapril, Captopril and Fosinopril in Pharmaceuticals and Serum by HPLC
Journal of Chromatography & Separation Techniques

Journal of Chromatography & Separation Techniques
Open Access

ISSN: 2157-7064

Research Article - (2013) Volume 4, Issue 4

Direct Determination of Four ACE-Inhibitors Lisinopril, Enalapril, Captopril and Fosinopril in Pharmaceuticals and Serum by HPLC

Sultana N1, Naveed S1,2* and Arayne MS3
1Research Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan
2Jinnah University for Women, Karachi, Pakistan
3Department of Chemistry, University of Karachi, Pakistan
*Corresponding Author: Naveed S, Research Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan Email:

Abstract

The high performance liquid chromatography (HPLC)-UV method for the simultaneous determination of lisinopril, enalapril, captopril and fosinopril in human plasma is proposed. Good separation of the analytes was achieved by gradient RP-HPLC with the mobile phase composed as acetonitrile: water (60:40 v/v) adjusted to pH 3.0 by orthophosphoric acid. Lisinopril, enalapril, captopril and fosinopril were eluted from a Purospher STAR RP-and Hypersil ODS column in 1.8, 2.9, 3.2 and 5.4 min respectively. Good linear relationships were observed for all of the analytes (R2 higher than 0.995). Intra and inter-day precision and accuracy results were 98.0 to 102%. Application of the suggested procedure was successfully applied to the determination of theses compounds in active pharmaceutical preparations, dosage formulations and human serum with high percentage of recovery, good accuracy and precision (no interference of excepients) and this method can be applied to routine clinical analysis

Keywords: HPLC; Lisinopril; Enalapril; Captopril; Fosinopril

Introduction

The ACE inhibitors block the angiotensin converting enzyme that cleaves the terminal two peptides from angiotensin I (decapeptide) to form the potent vasoconstrictor angiotensin II (octapeptide) [1,2] and lower the BP by reducing peripheral vascular resistance without increasing cardiac output rate and contractility. Comparatively, all ACE inhibitors (Figure 1) have similar antihypertensive efficacy they effectively block the conversion of angiotensin 1 to angiotensin II and all have similar therapeutic indications, adverse effect profile and contraindications.

chromatography-separation-techniques-ACE-inhibitors

Figure 1: Structure of ACE inhibitors.

Lisinopril, (S)-1-[N2-(1-carboxy-3-phenyl propyl) -L- lysyl] -Lproline dihydrate a lysine analogue of enalaprilate, is a white to off-white crystalline, odorless powder Enalapril(S)-1-[N-[1-(ethoxycarbonyl)-3- phenylpropyl]-L-alanyl]-L-proline,(Z)-2- butenedioate is the maleate salt of enalapril a derivative of 2-amino acid, L-alanine and L-proline. Enalapril is a pro-drug it is bioactivated by hydrolysis of the ethyl ester to enalaprilate active form.

Captopril 1-[(2S)-3-mercapto-2-methyl-1-oxo-proptonyl]-Lproline is the first orally active and specific inhibitor of angiotensinconverting enzyme. Fosinopril sodium chemically designated as L-proline, 4-cyclohexyl-l-[[[2-methyl-l-(l¬oxopropoxy) propoxy] (4-phenylbutyl) phosphinyl] acetyl]-, sodium salt, is an ester prodrug which is hydrolyzed to pharmacologically active fosinopril at a specific competitive inhibitor of angiotensin converting enzyme.

Several methods has been reported for determination of lisinopril [3-8] enalapril [9-15], captopril [16-21] and fosinopril [22] by HPLC alone or in combination with other drugs, but there is no single method reported for determination of these ACE inhibitors together.

The measurement of ACE-Inhibitors serum concentration is essential to optimize therapy and to avoid sub therapeutic or toxic concentrations particularly for patients with both impaired renal and hepatic functions. This paper describes an isocratic reversed-phase high performance liquid chromatographic method for the determination of four ACE-Inhibitors: lisinopril, enalapril, captopril and fosinopril. The isocratic HPLC method uses a simple mobile phase, UV-detection at 225 nm, and a simple sample-preparation step for serum samples. UV-detection is simple, rapid, selective, and reproducible, and sensitivity is adequate for routine use. Direct determination of the examined compounds in small volumes of human blood serum can be accomplished by protein precipitation using acetonitrile. The method was validated in terms of linearity, accuracy, precision, sensitivity, selectivity, and stability.

Experimental

Wavelength selection

In addition, the UV spectra of individual drugs were recorded in the wavelength range from 200 to 400 nm and overlap to each other. It was found that all the drugs exhibited the high response at 225 nm.

Sample preparation

Standard stock solution was prepared by dissolving 10 mg each of enalapril, captopril, lisinopril and fosinopril in the mobile phase and the volume made up to 100 mL with the same solvent. For the calibration curve, six calibrators of drugs were prepared by making serial dilutions from stock solution over the range of 5-100 μgmL-1.

Material and Reagents

Pharmaceutical grade enalapril was gifted by MSD Laboratories Limited, Karachi, Pakistan. Captopril, lisinopril and fosinopril were gifted from Bristol Meyers Pvt Ltd, Atco Laboratories Ltd respectively. Formulations of enalapril namely (renitec 10 mg), captopril (capoten 25 mg), lisinopril (lisinopril 10 mg) and fosinopril (fosinopril 10 mg) were obtained from retail pharmacies. All reagent used were of HPLC grade. Methanol and acetonitrile used were of HPLC grade from E. Merck, Germany. Orthophosphoric acid 85% used were of analytical grade (Merck, Germany). HPLC grade water was used to prepare mobile phase. Stock solutions and working solution were prepared daily. All solutions were filtered through 0.45 μm filter and degassed using sonicator.

Instrumentation

Shimadzu HPLC system equipped with a LC-10 AT VP pump, an SPD-10 AV VP UV–VIS dual wave length detector, integrated via Shimadzu model CBM-102 Communication Bus Module to P-IV computer. Shimadzu CLASS-GC software (Version 5.03) was used for data acquisition and mathematical calculations. Rheodyne manual injector fitted with a 20 μL loop. Chromatographic separation was carried out on a Purospher STAR RP-and Hypersil ODS column C-18 column (250×4.6 mm, with a particle size of 10 μ) and DGU- 14 AM on-line degasser. UV visible 1601 Shimadzu double beam spectrophotometer.

Assay in formulation

Twenty tablets of each lisinopril, enalapril, captopril and fosinopril were weighed to obtain the average tablet weight and then powdered. Equivalent to 10 mg of enalapril, 25 mg of captopril, 10 mg of lisinopril and 10 mg of fosinopril were weighed and the solution was made up to 100 mL with mobile phase. The resulting mixture was allowed to stand for 1 hour with intermittent sonication to ensure complete solubility of the drug (stock solution). This stock solution was filtered and the filtrate was diluted to the desired concentration. All sample and standard solutions were filtered through 0.45 μm filter paper before injection into the system. A placebo tablet was also subjected to the same process as discussed above. The possibility of excepients interference in the analysis was studied.

Assay in serum

Plasma samples, obtained from healthy volunteers, were collected and stored. To 1.0 mL of plasma, 9.0 mL of acetonitrile was added; the mixture was vortexed for 1 min and than centrifuged for 10 min at 10,000 rpm and the supernatant was filtered by 0.45-micron membrane filter. An aliquot of serum sample was fortified with lisinopril, enalapril, captopril and fosinopril to achieve final concentration.

Results and Discussion

Method validation

To optimize the operating conditions for isocratic RP-LC detection of all analytes, a number of parameters such as the mobile phase composition, pH and the flow rate were varied. Various ratios (50:50, 60:40, 70:30, v/v) of methanol: water was tested as starting solvent for system suitability study. The variation in the mobile phase led to considerable changes in the chromatographic parameters, like peak symmetry, capacity factor and retention time. The pH effect showed that optimized conditions are reached when the pH value was 3, producing well resolved and sharp peaks for all drugs assayed. Henceforth, in the present method pH adjusted to 3 using wavelength 225 nm (isobestic point) was used. However, the ratio of (60:40 v/v) ACN: water pH adjusted to 3 with phosphoric acid as mobile phase (filtered through a 0.45 micron filter), a flow rate of 1.0 mLmin-1 was chosen as optimal condition. The International Conference on Harmonization [23] has defined these validation parameters which are summarized below.

System suitability

Before sample analysis, six consecutive replicate analysis of the drugs at a concentration of 100 μgmL-1 for lisinopril, enalapril, captopril and fosinopril were assessed for repeatability, peak symmetry, theoretical plates and resolution. Results are depicted in Table 1, sharp and symmetrical peaks were obtained with good base line resolution (Figure 2).

chromatography-separation-techniques-Representative-chromatogram

Figure 2: Representative chromatogram of ACE inhibitors in API.

    % RSD
Parameters Lisinopril Enalapril Captopril Fosinopril
Retention time (Rt. In minutes) 0.006 0.003 0.021 0.025
Capacity factors (K’) 0.0000 0.0000 0.009 0.0090
Theoretical plates (N) 0.3661 0.0527 0.2551 0.008
Tailing factor (T) 1.311 1.1778 0.1127 0.0454
Resolution (R) 0.1023 0.0000 0.1220 0.1000
LLOD (Bulk material) ngmL-1 0.007 0.102 0.050 0.00
LLOD (Serum) ngmL-1 0.0325 0.0790 0.1294 0.010

Table 1: System suitability parameters sensitivity of the proposed method.

Specificity

The specificity of the method was observed by analyzing the pharmaceutical formulation. The excepients did not show any interference with the peak of ACE inhibitors. No significant changes in AUC or retention time of the drug in presence of excepients.

Range and linearity

Linearity studies were performed on 6 different concentrations. The calibration curves were linear in the range of 5-100 μgmL-1 for lisinopril, enalapril, captopril and fosinopril with correlation coefficient (r2) of ≥ 0.9997 (Table 2). Statistical soft ware was used to generate linear regression equations for all calibration curves.

Analytes Goodness of fit (r2) Standard error Standard error of estimate Intercept value Slope P
Bulk material
Lisinopril 0.999 10514 18750 31517 49133 0
Enalapril 0.999 4432 6217 47360 49953 0
Captopril 0.996 10515 1475 5399 60415 0
Fosinopril 0.999 7206 10108 32219 34600 0
In serum
Lisinopril 0.999 11058 18512 26548 49331 0
Enalapril 0.998 4352 6105 48474 49959 0
Captopril 0.999 7642 1020 5672 6381 0
Fosinopril 0.999 7378 10350 33125 34595 0

Table 2: Regression statistics of the proposed method.

Limit of detection and quantitation

LOD=3.3?/S and LLOQ= 0?/S; where ο is the standard deviation of the lowest standard concentration and S is the slope of the standard curve. The LOD for this assay were 0.9, 3.9, 2.0 and 0.5 ngmL-1 and limit of quantitation were 2.8, 12, 8 and 0.7 ngmL-1 for lisinopril, enalapril, captopril and fosinopril respectively.

Accuracy and precision

The precision was investigated with respect to repeatability (intraday precision) and intermediate precision (inter-day precision) and was expressed as relative standard deviation (RSD). These experiments were repeated over three days period to evaluate inter mediate precision. Accuracy of the method was determined by adding known amount of all analytes (lisinopril, enalapril, captopril and fosinopril) in the pharmaceutical formulations. All measurements were performed in triplicates (Tables 3 and 4).

  Lisinopril Enalapril Captopril Fosinopril
Conc. RSD Rec Rec. Conc. RSD Rec Rec. Conc. RSD Rec. Rec. Conc. RSD Rec. Rec. Conc.
5 0.77 99.6 4.98 0.9 101.76 5.35 0.94 100.54 5.22 0.94 100.5 40.22
10 0.07 101.47 10.15 0.79 100.2 10.1 0.6 100.37 10.3 0.6 100.4 80.3
15 0.8 99.95 14.99 0.02 100.87 15.5 0.46 100.06 15.07 0.46 100.1 120.1
20 0.65 99.85 19.97 0.75 100.11 20.1 0.12 100.43 20.69 0.12 100.4 160.7
25 0.18 100.07 25.01 0.7 100.09 25.1 0.09 100.11 25.21 0.09 100.1 200.2
50 0.11 100.02 50.01 0.22 99.98 50 0.14 99.97 50.9 0.14 99.97 399.9
Spiking (Bulk material -- % level)
80 0.12 99.95 8 0.37 99.92 7.99 0.12 99.95 8 0.25 100.2 8.01
100 0.22 100.06 10.01 0.16 99.9 9.99 0.22 100.06 10 0.12 99.95 10
120 0.36 99.69 11.96 0.09 99.92 12 0.36 99.69 12 0.06 99.88 11.99
Spiking (Serum -- % level)
80 0.13 100.02 8 0.34 100.05 8 0.37 99.92 7.99 0.25 100.2 8.01
100 0.15 100.17 10.02 0.13 99.87 9.99 0.16 99.9 9.99 0.12 99.95 10
120 0.332 100.11 12.01 0.09 99.94 12 0.09 99.92 11.99 0.06 99.88 11.99

Recovery (Rec.) and RSD in %; Concentration (Conc.) and Recovered Concentration (Rec. Conc.) in μgmL-1.

Table 3: Method accuracy from recovery assays for the studied analytes.

Conc. Day 1 (%RSD) Day 2 (%RSD) Day 3 (%RSD)
µgmL-1 LSP ENP CAP FSP LSP ENP CAP FSP LSP ENP CAP FSP
(Bulk material)
5 0.351 0.016 0.390 0.044 0.062 0.459 0.309 0.122 0.115 0.341 0.069 0.076
10 0.116 0.025 0.101 0.098 0.070 0.048 0.140 0.014 0.079 0.249 0.020 0.136
15 0.149 0.035 0.007 0.024 0.009 0.018 0.117 0.291 0.032 0.061 0.118 0.112
20 0.003 0.070 0.055 0.000 0.015 0.219 0.012 0.104 0.012 1.005 0.064 0.004
25 0.017 0.019 0.081 0.023 0.065 0.019 0.124 0.006 0.011 0.003 0.260 0.063
50 0.056 0.014 0.110 0.055 0.029 0.402 0.002 0.107 0.004 0.620 0.049 0.024
(Serum)
5 0.452 1.009 0.021 0.380 0.083 0.509 0.060 0.003 0.125 0.341 0.069 0.076
10 0.353 0.431 0.039 0.488 0.030 0.208 0.160 0.050 0.079 0.249 0.020 0.536
15 0.098 0.095 0.049 0.162 0.024 0.021 0.004 0.119 0.032 0.061 0.108 0.112
20 0.140 1.007 0.620 0.123 0.103 0.107 0.043 0.021 0.012 1.005 0.004 0.098
25 0.006 0.011 0.108 0.079 0.028 0.008 0.001 0.035 0.010 0.003 0.260 0.163
50 0.187 0.109 0.143 0.083 0.006 0.303 0.006 0.005 0.008 0.620 0.049 0.224

Table 4: Intra-and inter day, variation\intermediate precision of the method.

Ruggedness

The ruggedness was established by determining lisinopril, enalapril, captopril and fosinopril using the same chromatographic system and the same column by two analysts on different days. The results indicated that the method was capable with high precision. Additionally good separations were achieved which suggested that the method was selective for all components under the test (Table 4).

Robustness

Robustness of the methods was checked by making small deliberate changes in the mobile phase (± 5%), pH (± 0.01) and flow rate. These variations had a minor effect in operating conditions. One parameter was changed in the experiments at a time and assays were carried out in triplicate.

Applicability of method

The developed method was applied for the determination of drug content in marketed formulations (Figure 3). Similarly the % recoveries and r2 of dugs in presence of serum shown in (Figure 4) that the applicability of method for therapeutic purposes also.

chromatography-separation-techniques-Representative-chromatogram

Figure 3: Representative chromatogram of ACE inhibitors in formulations.

chromatography-separation-techniques-Representative-chromatogram

Figure 4 Representative chromatogram of ACE inhibitors in human serum.

Conclusion

After studying all the results obtained by HPLC studies it was concluded that the present method was fast and easy to perform, having low LLOQ and LLOQ values, was found to be linear up to a wide range of analytes and showing high % of recoveries. So, this method is good for the simultaneous determination of ACE Inhibitors (lisinopril, enalapril, captopril and fosinopril) in dosage formulation. This method is used for therapeutic purpose also. Moreover, in quality control lab it can be effectively and efficiently used to save time and excessive use of chemicals by preparing single samples for all the drugs to be assayed.

References

  1. Richard AH, Pamela CC (1977) Lippincott, Illustrated Review Pharmacology, Lippincott-Raven Publishers, Philadelphia, Revised ed, 151-162.
  2. Bertam GK, Basic and Clinical Pharmacology. Appleton and Lange, (1998) Revised ed, 197-213.
  3. Sane RT, Valiyare GR, Deshmukh UM, Singh SR, Sodhi R (1992) Simultaneous HPLC determination of lisinopril and hydrochlorothiazide from its pharmaceutical preparations. Indian Drugs, 29(12): 558-560.
  4. Naveed S, Sultana N, Arayne MS (2012) Simultaneous determination of lisinopril and H2 antagonists in API, formulations and human serum by using two different HPLC systems. Medicinal Chemistry Research 21: 4037-4042.
  5. Aytan F, Alpdogan G, Sungur S (2007) High pressure liquid chromatographic investigation of the pH and temperature effect on the solution of lisinopril. Reviews in Analytical Chemistry 26: 55-64.
  6. El-Emam AA, Hansen SH, Moustafa MA, El-Ashry SM, El-Sherbiny DT (2004) Determination of lisinopril in dosage forms and spiked human plasma through derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) followed by spectrophotometry or HPLC with fluorimetric detection. J Pharm Biomed Anal 34: 35-44.
  7. Najma S, Arayne MS, Safila N (2011) Validated Method for the Simultaneous Determination of Lisinopril, Pravastatin, Atorvastatin and Rosuvastatin in API, Formulations and Human Serum by RP-HPLC. Chinese Journal of Chemistry 29: 1216-1220.
  8. Sultana N, Arayne MS, Siddiqui R, Naveed S (2012) RP-HPLC Method for the Simultaneous Determination of Lisinopril and NSAIDs in API, Pharmaceutical Formulations and Human Serum. American Journal of Analytical Chemistry 3: 147-152.
  9. Rau HL, Udupa N, Aroor AR (1991) A new HPLC method for the estimation of enalapril maleate in tablets. Indian Drugs, 29(1), 46-48.
  10. Arayne MS, Sultana N, Zuberi MH, Siddiqui FA, Haroon U (2013) Simultaneous determination of metformin, captopril, lisinopril, and enalapril by RP-HPLC: its applications in dosage formulations and in human serum. Medicinal Chemistry Research
  11. Naveed S, Sultana N, Arayne MS (2012) HPLC-UV Method for the Determination of Enalapril in Bulk, Pharmaceutical Formulations and Serum. J Anal Bioanal Techniques 3: 130.
  12. Arayne MS, Tabassum A, Ali SN, Sultana N, Naveed S (2012) Simultaneous LC determination of rosuvastatin, lisinopril, captopril, and enalapril in API, pharmaceutical dosage formulations, and human serum. Medicinal Chemistry Research 21: 4542-4548.
  13. Sultana N, Arayne MS, Naveed S, Shamshad H (2009) An RP-HPLC Method for Simultaneous Analysis and Interaction Studies on Enalapril Maleate and H2-Receptor Antagonists. Acta Chromatographica 21: 547–558.
  14. Sultana N, Arayne MS, Naveed S (2011) Simultaneous Determination of Enalapril and statins in pharmaceutical formulations by RP- HPLC. J Chil Chem Soc 56: 734-737.
  15. Sultana N, Naveed S, Arayne MS (2013) Monitoring of in vitro interaction studies of Enalapril with Hypoglycemic agents by LC-UV. Research and Reports in Medicinal Chemistry 1–7
  16. Ahmed S, Rizk M ,Belal F, Ibrahim F, Sheribah ZA (2006) Stability-Indicating HPLC method for captopril through Pre-Column derivatization with Pd(II), Journal of Liquid Chromatography & Related Technologies 29: 521– 532.
  17. Sultana N, Arayne MS, Naveed S (2011) RP-HPLC method for simultaneous determination of captopril and diuretics: application in pharmaceutical dosage forms and human serum. J Chromatograph Separat Techniq 2: 109.
  18. Stulzer HK, Tagliari MP, Kuminek G , Oliveira PR, Bertol CD, et al. (2009) Development and validation of stability indicating LC method to quantify captopril in tablets of controlled release, Chromatographia 69: 123-128.
  19. Ivanovic D, Medenica M, Malenovic A, Jancic B (2004) Validation of the RP-HPLC method for analysis of hydrochlorothiazide and captopril in tablets. Accreditation and Quality Assurance 9: 76-81.
  20. Sultana N, Arayne MS, Naveed S (2010) Simultaneous Quantitation of Captopril and NSAID’s in API, Dosage Formulations and Human Serum by RP-HPLC. Journal of the Chinese Chemical Society 57: 62-67.
  21. Sultana N, Arayne MS, Naveed S (2010) Simultaneous determination of Captopril and Statins in API, Pharmaceutical Formulations and in Human Serum by RP-HPLC. Journal of the Chinese Chemical Society 57: 378-383.
  22. Saglik S, Sagirli O, Atmaca S, Ersoy L (2001) Simultaneous determination of fosinopril and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods. Analytica Chimica Acta 427: 253-257.
  23. Validation of Analytical Procedures: Text and Methodology Q2(R 1) (2005) ICH Harmonised Tripartite Guideline International Conference on Hormonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
Citation: Sultana N, Naveed S, Arayne MS (2013) Direct Determination of Four ACE-Inhibitors Lisinopril, Enalapril, Captopril and Fosinopril in Pharmaceuticals and Serum by HPLC. J Chromat Separation Techniq 4:179.

Copyright: © 2013 Sultana N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.